Brentuximab vedotin for CTCL

Evangelina Papadavid, MD, PhD, National and Kapodistrian University of Athens, Athens, Greece, talks on the use of brentuximab vedotin in the treatment of mycosis fungoides, a subtype of cutaneous T-cell lymphoma (CTCL), highlighting a response rate of over 60%, which has also been observed in real-world data. Prof. Papadavid also comments on a response rate of over 10% in patients who are CD30-negative, and in some cases of Sézary syndrome. Finally, Prof. Papadavid discusses the benefits of using brentuximab vedotin in the frontline setting. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.